Detalhe da pesquisa
1.
First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors.
Cancer
; 126(22): 4926-4935, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32809217
2.
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
N Engl J Med
; 374(26): 2542-52, 2016 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27093365
3.
Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
J Immunother Cancer
; 10(9)2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36100308
4.
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors.
Clin Cancer Res
; 27(7): 1904-1911, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355238
5.
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
Eur J Cancer
; 131: 68-75, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32305010
6.
Corrigendum to "A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation" [Eur J Canc 131 (2020) 68-75].
Eur J Cancer
; 144: 400, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33414065
7.
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Clin Ther
; 25(6): 1700-21, 2003 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12860493
8.
Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
J Rheumatol
; 41(4): 648-57, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24584918
9.
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
Arch Dermatol
; 144(2): 200-7, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18283176
10.
Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis.
J Rheumatol
; 32(5): 811-9, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15868614
11.
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
J Rheumatol
; 30(12): 2563-71, 2003 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-14719195
12.
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Arthritis Rheum
; 50(5): 1400-11, 2004 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15146409
13.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
Arthritis Rheum
; 48(1): 35-45, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12528101